Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation.

Breast cancer research and treatment - 1 Apr 2014

Møller Pål, Stormorken Astrid, Holmen Marit Muri, Hagen Anne Irene, Vabø Anita, Mæhle Lovise

Abstract excerpt

We report prospectively observed risk for breast cancer in breast cancer kindreds without a demonstrable BRCA1/2 mutation. According to family history, the optimal available member(s) of each breast cancer kindred attending our clinic was tested for BRCA mutations. Women in families without a demonstrable BRCA mutation were subjected to annual mammography. BRCA mutations were demonstrated in 496/2,118 (23 %)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Hereditary Breast and Ovarian Cancer Syndrome

Share to Incidence

Share to Norway

Source

Open in PubMed Open full text

Identifiers

PMID: 24619173
DOI: 10.1007/s10549-014-2902-1
PMCID: PMC3962741

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation.PMID 24619173Read ↗

Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers.Semantic proximity Read ↗

Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.Semantic proximity Read ↗

[Genes beyond BRCA1 and BRCA2 for hereditary breast cancer].Semantic proximity Read ↗

BRCA2: a genetic risk factor for breast cancer.Semantic proximity Read ↗

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.Semantic proximity Read ↗

Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.Semantic proximity Read ↗

No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families.Semantic proximity Read ↗

The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.Semantic proximity Read ↗

No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.Semantic proximity Read ↗

Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.Semantic proximity Read ↗

BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.